Technology name
Last update: Jul 2026Long-Acting Injectable Solid Drug Nanoparticle (SDN) Platform
Sponsor(s)
Type of technology
Aqueous drug particle suspension
Administration route
Development state and regulatory approval
Rifapentine
Pre-clinical
Not provided
Description
The use of particle processing technology to generate long-acting injectable nanoparticle formulations for long-acting delivery.
Developer(s)
Tandem Nano
A University of Liverpool based start-up company using proprietary technology for the generation of novel nanoparticle formulations to improve the delivery of poorly water soluble APIs.
University of Liverpool
Centre for Excellence of Long-acting Therapeutics
Technology highlight
The generation of high drug-loading nanoparticles with prolonged release for poorly water-soluble drugs with the potential for co-formulation strategies.
Illustration(s)
Technology main components
Active pharmaceutical ingredients, FDA/CDER listed excipients.
Safety, Efficacy and Evidence Summary
To be determined
Not provided
Not provided
Not provided
APIs compatibility profile
Unit: mg/mL
To be determined.
Multiple.
None.
-
75-90 wt%
2 different APIs : API dependent.
Not provided
Scale-up and manufacturing prospects
To be determined
To be determined
To be determined
To be determined
Excipients & delivery device(s)
No proprietary excipient used
No novel excipient or existing excipient used
No residual solvent used
No delivery device
Additional features
Not provided
To be determined
To be determined
To be determined
To be determined
Therapeutic area(s)
- Disease agnostic
Not provided
Potential associated API(s)
- Rifapentine
- Atovaquone
- Glecaprevir (G)
- Pibrentasvir (P)
Use of technology
- Administered by a community health worker
- Administered by a nurse
- Administered by a specialty health worker
- Self-administered
Daily
Targeted user groups
- Adults
- All
- Male
- Female
- Cisgender female
- Cisgender male
- Transgender female
- Transgender male
- Intersex
- Gender non-binary
Unspecified
Unspecified
Unspecified
Not provided
Rifapentine
Not provided
Pre-clinical
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pre-clinical
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided